MedTrace Logo

Study to Evaluate the Safety and the Pharmacokinetics of IY-NT-T

NCT05617651 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2023-03-01

No results posted yet for this study

Summary

This study evaluate the pharmacokinetic and safety of IY-NT-T in healthy adults

Conditions

  • Pharmacokinetics

Interventions

DRUG

IY-NT-T

Ilaprazole 20mg

DRUG

IY-NT-R

Ilaprazole 10mg

Sponsors & Collaborators

  • Il-Yang Pharm. Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jae Woo Kim, MD, PhD · H Plus Yangji Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-11-30
Primary Completion
2024-12-10
Completion
2025-12-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05617651 on ClinicalTrials.gov